Lupus Foundation Statement on Administration's Most Favored Nation Drug Pricing Rule
November 26, 2020
November 26, 2020
WASHINGTON, Nov. 26 -- The Lupus Foundation of America issued the following statement:
The Lupus Foundation of America supports efforts to lower patient out of pocket costs in Medicare Part B, which provides people with lupus access to critical medications including the only drug approved to treat the disease.
However, we are deeply concerned that the Administration's Most Favored Nation rule may limit patient access to current and future therapies.
Moreo . . .
The Lupus Foundation of America supports efforts to lower patient out of pocket costs in Medicare Part B, which provides people with lupus access to critical medications including the only drug approved to treat the disease.
However, we are deeply concerned that the Administration's Most Favored Nation rule may limit patient access to current and future therapies.
Moreo . . .